Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sophiris amends plans for NASDAQ listing, follow-on

Sophiris Bio Inc. (TSX:SHS) amended its plans to list on NASDAQ and said

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE